Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 360 participants.

Also called NCT07193459

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 360 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07193459
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07193459. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-12 (actual); primary completion 2026-10-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
Intervention (Drug)
HDM1002 200 mg
Intervention (Drug)
HDM1002 400 mg
Intervention (Drug)
Placebo
Lead sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07193459
Content hash
d452b495a2e0b1e6410f980a91ab36d0316a926fe6f789c1c0ffdbd6e34515d9